{"doi":"10.1002/ctm2.70555","title":"The ‘vulnerability code’: Is cell identity the architect of its own decay?","abstract":"The establishment and maintenance of cellular identity depend on two fundamental yet historically separately studied mechanisms: DNA repair machineries that safeguard genome fidelity, and epigenetic programs that regulate cell-type-specific gene expression patterns.1 Research on DNA damage repair has primarily emphasised the molecular pathways and kinetics of the DNA damage response.2 Conversely, investigations on epigenetics have focused on how cells establish and sustain their transcriptional memory.3 This disciplinary separation has created a blind spot: while we understand how the hardware (genome integrity) fails and how the software (epigenetic regulation) becomes compromised, the question of whether and how the former impairs the latter remains unresolved. Recent research indicates that these two processes are interconnected. The link between them is recognised through the understanding that DNA damage constitutes an effective ‘toxic modification’ that influences gene regulation. When cells experience genotoxic stress, chromatin temporarily relaxes to permit the access of repair factors to DNA; this process involves the phosphorylation of histone H2AX and the recruitment of chromatin remodellers.4 Ideally, these changes are transient and are reversed once the damage has been repaired. However, some modifications may not be fully reversed, leaving persistent epigenetic ‘scars’ that affect gene expression long after the repair process.2 Conversely, the existing epigenetic context influences the genome's vulnerability: heterochromatin regions tend to undergo slower repair, while active regions such as promoters and enhancers are more accessible but also more prone to damage caused by transcriptional activity or toxins.5 This results in a complex, system-wide challenge: the concept that chromatin modifiers are repurposed for DNA repair suggests that the balance of cell survival and proper functioning involves an ongoing conflict at the molecular level. This bidirectional relationship constitutes a ‘systems level’ issue: the ‘relocalization of chromatin modifiers’ theory proposes that the machinery used for repairing DNA breaks is frequently borrowed from the epigenetic maintenance system, leading to a direct conflict between the maintenance of cell survival and the preservation of cellular function.6 These findings challenge the long-held view in the field that DNA damage occurs randomly primarily due to thermodynamic noise and environmental factors. If DNA damage hotspots can be precisely identified, the trajectory of cellular decline may become more predictable, as the initial regulatory failure can be specifically targeted. The susceptibility of organs to DNA damage varies considerably among mammals: the most vulnerable are energy-dense tissues such as the brain, owing to their reliance on abundant redox-active compounds. Indeed, within the nervous system, long-lived cells tend to accumulate damage over extended periods, highlighting the importance of these mechanisms in neural aging and pathology. Recent studies have demonstrated significant correlations between elevated DNA damage, the gradual decline of the epigenetic landscape and the development of age-related neurodegenerative disorders,7, 8 indicating that an imbalance between DNA repair mechanisms and epigenetic stability may contribute to neuronal aging and disease progression. This creates a major technical challenge: precisely identifying damage hotspots across different cell types within complex, heterogeneous tissues. To bridge this gap, we developed Paired-Damage-seq, a method for single-cell parallel analysis of oxidative and single-strand DNA breaks alongside the transcriptome.9 We first benchmarked Paired-Damage-seq in a cultured cell line: the specificity of damage detection was validated against previously established bulk assays, and the sensitivity was evaluated using publicly available single-cell datasets (of transcriptome and epigenome). Additiona","journal":"Clinical and Translational Medicine","year":2025,"id":585341,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.953,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2025-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1329754,"name":"Zhenkun Cao","orcid":"0009-0005-3968-8994","position":1,"is_corresponding":false},{"id":6256,"name":"Chenxu Zhu","orcid":"0000-0003-4216-6562","position":2,"is_corresponding":false},{"id":1498705,"name":"Dong-sheng Bai","orcid":"0009-0005-9905-781X","position":0,"is_corresponding":true}],"reference_count":10,"raw_metadata":null,"created_at":"2026-07-19T02:59:20.067334Z","pmid":"41399166","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}